Annals

The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment

Edited by Edited by Jerry M. Rice (Georgetown University, Washington, D.C.)
Explore the Table of Contents
The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment

Published: March 2014

Volume 1310

Learn More

Over 20,000 Americans are diagnosed each year with bone marrow failure syndromes. Environmental, chemical, and genetic factors have been linked to the development of lymphomas, leukemias, and myelodysplastic syndromes (MDS). Additionally, some anti-cancer drugs have been shown to themselves induce DNA damage and secondary cancers. To date, two separate groups of scientists and physicians have been studying bone marrow: toxicologists who examine the effects of chemicals and the environment on healthy marrow, and hematologists and oncologists who investigate bone marrow abnormalities and malignancies. There is a clear unmet need for collaboration between these fields within academia, industry, and government in order to accelerate our investigation and understanding both of basic bone marrow biology and chemically-induced diseases of the marrow.

This Annals volume explores research conducted by experimental hematologists, clinicians, and toxicologists that examines hematopoietic stem cells, the bone marrow environment in which they reside, and the diseases that result from their neoplastic transformation. These interdisciplinary papers stem from the conference, “The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment,” sponsored by the New York Academy of Sciences and Rutgers University, and held May 29–31, 2013, at the New York Academy of Sciences in New York City. A range of topics are covered, including bone marrow niche structure and function, the maturation and differentiation of healthy and leukemogenic hematopoietic stem cells, and the environmental, chemical, and genetic factors involved in the development of myeloid abnormalities, including MDS and acute myeloid leukemia (AML).